Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 2- Application to Head-and-Neck Cancer Patients (original) (raw)
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity
Cedric Mercier, Bruno Lacarelle
Cancer Chemotherapy and Pharmacology, 2011
View PDFchevron_right
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction
Romano Danesi
British Journal of Clinical Pharmacology, 2009
View PDFchevron_right
Measurement of 5-FU plasma levels in patients with advanced cancer: correct approach to practical procedures is essential
Silke Cameron
International journal of clinical pharmacology and therapeutics
View PDFchevron_right
Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil–Related Severe Toxicities: Hype or Hope?
Cedric Mercier
Clinical Colorectal Cancer, 2010
View PDFchevron_right
No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion
François Demard
British Journal of Cancer, 1992
View PDFchevron_right
Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer
Antoine Thyss, Maurice Schneider
Cancer Chemotherapy and Pharmacology, 1986
View PDFchevron_right
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases
Cedric Mercier, Bruno Lacarelle
Cancer Chemotherapy and Pharmacology, 2011
View PDFchevron_right
Measurements of 5-FU Plasma Concentrations in Patients with Gastrointestinal Cancer: 5-FU Levels Reflect the 5-FU Dose Applied
Silke Cameron
Journal of Cancer Therapy, 2012
View PDFchevron_right
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer
François Demard
British journal of …, 1989
View PDFchevron_right
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity
Romano Danesi
Clinical pharmacology and therapeutics, 2006
View PDFchevron_right
Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity
Robert Diasio
British Journal of Clinical Pharmacology, 2007
View PDFchevron_right
A phase III study comparing the clinical utility of four regimens of 5Fluorouracil.A preliminary report
Guillermo Ramírez
Cancer, 1977
View PDFchevron_right
Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5-fluorouracil therapy
Ozden Altundag
Medical Hypotheses, 2005
View PDFchevron_right
A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach
Adam Lee
Mayo Clinic proceedings, 2014
View PDFchevron_right
Pharmacokinetics of 5-FU in experimental regional chemotherapy
Maurice Nahabedian
Cancer Research
View PDFchevron_right
Bimonthly 24 h Infusion of High-Dose 5Fluorouracil vs EAP Regimen in Patients with Advanced Gastric Cancer
marjan babić
Medical Oncology, 2008
View PDFchevron_right
Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial
brian stein
Cancer, 1995
View PDFchevron_right
Potential of Dihydropyrimidine Dehydrogenase Genotypes in Personalizing 5-Fluorouracil Therapy Among Colorectal Cancer Patients
Suneet Sood
Therapeutic Drug Monitoring, 2013
View PDFchevron_right
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing
Sarah Glewis, Hamizan Khabib
British Journal of Cancer, 2022
View PDFchevron_right
DoseVersus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5FU
roger khater
International Journal of Cancer, 1988
View PDFchevron_right
Assessment of Infusional 5-Fluorouracil Schedule and Dose Intensity: A Southwest Oncology Group and Eastern Cooperative Oncology Group Study
Heinz-josef Lenz
Clinical Colorectal Cancer, 2005
View PDFchevron_right
Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation
Elisa Giorgio
Cancer Chemotherapy and Pharmacology, 2011
View PDFchevron_right
Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography–tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity
erdim sertoğlu
Cancer Chemotherapy and Pharmacology, 2011
View PDFchevron_right
PCN24: Incidence and Cost of Hospitalization for 5-FU Toxicity Among Medicare Beneficiaries with Metastatic Colorectal Cancer
Montserrat Vera
Value in Health, 2001
View PDFchevron_right
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin
Mei-ling Hou
Journal of Translational Medicine, 2013
View PDFchevron_right
Clinical Suspicion &Dihydropyrimidine Dehydrogenase (DPD) Mutation Positivity In Patients Receiving Chemotherapy With Capecitabine / 5 Fluorouracil (5 FU
IOSR JDMS
View PDFchevron_right
Toxicity and Efficacy of 5Fluorouracil and Capecitabine in a Patient With TYMS Gene Polymorphism: A Challenge or a Dilemma
Armin Shahrokni
Clinical Colorectal Cancer, 2009
View PDFchevron_right
Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer
Kailash Narayan
European Journal of Cancer, 1996
View PDFchevron_right
Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study
Cristina Montomoli
Journal of Neurology, 2018
View PDFchevron_right
Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group
Jürgen Dippon
Journal of Clinical Oncology, 2008
View PDFchevron_right
A systematic review on the importance of genotyping and phenotyping in fluoropyrimidine treatment
Claudia Burz
Medicine and Pharmacy Reports
View PDFchevron_right
13C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients
Gerson Pianetti
Cancer Chemotherapy and Pharmacology, 2013
View PDFchevron_right